Impact of Anti PD-1 Therapy in Children, Adolescents and Young Adults (CAYA) Melanoma Patients
This is a retrospective observational cohort study, the primary objective is investigate the activity and efficacy of anti PD-1 antibodies in children, adolescents and young adult melanoma patients, with radically resected or metastatic disease
- EligibilityCriteria: Inclusion Criteria:  Patients of either sex aged ≥ 12 years; Histologically confirmed melanoma; Anti PD-1 Immunotherapy (Ipilimumab plus Nivolumab); Previous and subsequent treatments will be collected; Clinical and follow-up data available  Exclusion Criteria:  No immunotherapy received; No melanoma; Age > 30 yrs - HealthyVolunteers: No - Gender: All - MinimumAge: 12 Years - MaximumAge: 30 Years - StdAgeList: Child, Adult - StudyPopulation: Adolescent, childhood and young adult with early and advanced melanomas treated with anti PD-1 therapy - SamplingMethod: Probability Sample